Researchers ar the Kobe University Graduate School of Medicine, Division of Metabolomics, have unveiled a new diagnostic blood test for early screening of pancreatic cancer. Utilizing metabolomics technology, the blood test measures metabolite levels in order to determine whether or not patients are afflicted with a pancreatic tumor. According to lead researcher Dr. Masaru Yoshida, "finding pancreatic cancer earlier means more patients can have the tumor removed and live longer than most patients do now." Considering that the 5-year survival rate for pancreate cancer is less than 5%, this new approach seeks to detect pancreatic cancer at an early stage, before it metastasizes to the point that it becomes inoperable.
To read more about this study, click here
Source mentioned: Yoshida, M et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4)1-9.
No comments:
Post a Comment